ReviewCancer cell international2026
Potential correlation between high SNHG expression and poor pancreatic cancer prognosis: evidence from systematic reviews and meta-analyses.
Review in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNumerous studies have confirmed the upregulation of the long non-coding small nucleolar RNA host gene (SNHG) family in pancreatic cancer (PC) tissues, indicating its significant implications for PC prognosis. This research performed a meta-analysis to investigate whether the expression levels of SNHGs are correlated with PC prognosis.
methodsSix relevant electronic databases were searched, and original documents were screened for relevance. Moreover, the research quality of every document was analyzed through the NOS scale. Data extraction involved the retrieval of information regarding SNHG expression levels, survival outcomes, and follow-up durations. Odds ratios (ORs) and Hazard ratios (HRs) were combined with 95% confidence intervals (CIs) to assess the association between SNHG expression and overall survival (OS), depth of invasion, tumor size, and Tumor Node Metastasis (TNM) stage. To investigate potential publication bias, sensitivity analyses, and Begg’s test were carried out.
resultsCombining HRs with 95% CIs depicted that a considerable positive association exists between the elevated expression of SNHG and poorer OS (HR: 1.228, 95% CI: 1.142–1.315). Moreover, high SNHG expression was linked to higher histological grade (OR: 1.460, 95% CI: 1.149–1.856), increased likelihood of lymph node metastasis (OR: 1.818, 95% CI: 1.436–2.302), larger tumor size (OR: 1.500, 95% CI: 1.195–1.884), and advanced TNM stage (OR: 2.000, 95% CI: 1.569–2.549). Conversely, no considerable correlation was found between SNHG expression and age (OR: 0.983, 95% CI: 0.800-1.208), distant metastasis (DM) (OR: 1.725, 95% CI: 0.970–3.065), depth of invasion (OR: 1.456, 95% CI: 0.892–2.377), or gender (OR: 1.077, 95% CI: 0.848–1.369). The sensitivity analysis supported the robustness and reliability of OS findings, whereas Begg’s test revealed an absence of significant publication bias in the original literature.
conclusionMost SNHGs were highly expressed in PC tissues, with elevated levels correlating with a poor prognosis for PC. SNHGs hold promise as both potential targets for tumor therapy and valuable prognostic markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.